Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research

(2016) Victoria T. Potter et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

(2016) Brian C. Shaffer et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies

(2015) Dominik Schneidawind et al.   ANNALS OF HEMATOLOGY

Monosomal Karyotype at the Time of Diagnosis or Transplantation Predicts Outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome

(2015) Celalettin Ustun et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation

(2015) M Kim et al.   BONE MARROW TRANSPLANTATION

Are Hypomethylating Agents Replacing Induction-Type Chemotherapy before Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome?

(2014) Ibrahim Yakoub-Agha et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R

(2014) M. G. Della Porta et al.   BLOOD

Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia

(2013) Yi-Bin Chen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation

(2013) Rainer Storb et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

(2013) F Traina et al.   LEUKEMIA

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS

(2012) H. J. Deeg et al.   BLOOD

Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure

(2012) S-H Shin et al.   BONE MARROW TRANSPLANTATION

Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes

(2012) Seung-Ah Yahng et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies

(2012) Gandhi Damaj et al.   JOURNAL OF CLINICAL ONCOLOGY

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

(2012) Julie Schanz et al.   JOURNAL OF CLINICAL ONCOLOGY

Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome

(2011) Gheath Alatrash et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia

(2011) J.-H. Lee et al.   BLOOD

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

(2011) Thomas Prébet et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

(2011) U Platzbecker et al.   LEUKEMIA

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome: A Review

(2011) Simrit Parmar et al.   SEMINARS IN ONCOLOGY

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia

(2010) J. Choi et al.   BLOOD

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome

(2010) M. G. Della Porta et al.   HAEMATOLOGICA

Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome

(2010) Brian L. McClune et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries

(2010) Stuart L. Goldberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic Stem Cell Transplantation for Adults with Myelodysplastic Syndromes: Importance of Pretransplant Disease Burden

(2009) Erica D. Warlick et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting

(2009) L. I. Sanchez-Abarca et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation

(2009) T Field et al.   BONE MARROW TRANSPLANTATION

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity

(2009) J-H Lee et al.   BONE MARROW TRANSPLANTATION

The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome

(2009) E. Zipperer et al.   HAEMATOLOGICA

Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia

(2009) ZiYi Lim et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Pretransplant Neutropenia Is Associated with Poor-Risk Cytogenetic Features and Increased Infection-Related Mortality in Patients with Myelodysplastic Syndromes

(2008) Bart L. Scott et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

(2008) E. P. Alessandrino et al.   BLOOD

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

(2008) Hagop Kantarjian et al.   CANCER

Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype

(2008) Dimitri A. Breems et al.   JOURNAL OF CLINICAL ONCOLOGY

Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival

(2007) David Valcárcel et al.   JOURNAL OF CLINICAL ONCOLOGY